Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~Dyslipidemic subject who is currently undergoing statin therapy and no change in lipid-lowering therapy or dose during the 4 week prior to randomization~Exclusion criteria:~1. Recent (i.e.,\<6 months prior to screening) CV event and/or vascular procedure defined as:~   A)ST-elevation MI or non-ST-elevation MI B)Unstable angina C)Coronary revascularization \[(percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\] D)Stroke of any etiology E)Peripheral arterial disease with critical limb ischemia (resting pain or ischemic skin lesions, either ulcers or gangrene) F)Resuscitated cardiac arrest~2. Planned CABG or planned PCI or planned major non-cardiac surgery within study period~3. No measurable Lp-PLA2 activity in plasma (\<10 nmol/min/mL) at screening~4. Change in a lipid-lowering medication, regimen or dosage during the 4 week prior to randomization~5. Poorly controlled dyslipidemia (LDL-c \>=160 mg/dL) at screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Group (Type: PLACEBO_COMPARATOR): Matched Placebo
- SB480848 40mg Group (Type: EXPERIMENTAL): SB480848 40mg/day
- SB480848 80mg Group (Type: EXPERIMENTAL): SB480848 80mg/day
- SB480848 160mg Group (Type: EXPERIMENTAL): SB480848 160mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).